Physician profile
Marcus Y Chu
NPI 1609188614
$1,918.85
in general payments reported to CMS, 2019-2025
26 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $304 · 2020: $306 · 2021: $625 · 2022: $219 · 2023: $92.11 · 2024: $175 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $415 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.81 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $410.02 | 2021-2025 | Vraylar |
| Baxter Healthcare | $181.29 | 2022 | |
| Novo Nordisk INC | $175.15 | 2019-2021 | |
| Amarin Pharma, INC. | $141.46 | 2020-2021 | |
| Pfizer INC. | $116.19 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $108.39 | 2020-2021 | |
| Amgen INC. | $100.06 | 2019-2021 | |
| Lilly USA, LLC | $91.13 | 2021-2022 | |
| Glaxosmithkline, LLC. | $75.28 | 2020-2021 | |
| Astellas Pharma US INC | $61.80 | 2019 | |
| Allergan, INC. | $59.96 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.26 | 2021 | |
| Currax Pharmaceuticals LLC | $50.00 | 2023 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.48 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $33.87 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $28.39 | 2019 | |
| Kyowa Kirin, INC. | $27.96 | 2020 | |
| Sanofi-Aventis U.S. LLC | $24.98 | 2020-2021 | |
| Abbott Laboratories | $24.96 | 2025 | Cardiomems |
| Esperion Therapeutics, INC. | $24.77 | 2021 | |
| Nevro Corp. | $20.44 | 2024 | Senza |
| Phadia US INC. | $19.81 | 2021 | |
| Horizon Therapeutics Plc | $16.20 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.54 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.33 | 2020 | |
| Genentech USA, INC. | $11.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.